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Abstract
Previous studies have suggested that tumor hypoxia
could be exploited for cancer gene therapy. Using
hypoxia-responsive elements derived from the human
vascular endothelial growth factor gene, we have
generated vectors expressing a bacterial nitroreductase
(NTR) gene that can activate the anticancer prodrug
CB1954. Stable transfectants of human HT1080 tumor
cells with hypoxia- inducible vectors were established
with G418 selection. Hypoxic induction of NTR protein
correlated with increased sensitivity to in vitro exposure
of HT 1080 cells to the prodrug. Growth delay assays
were performed with established tumor xenografts
derived from the same cells to detect the in vivo efficacy
of CB1954 conversion to its cytotoxic form. Significant
antitumor effects were achieved with intraperitoneal
injections of CB1954 both in tumors that express NTR
constitutively or with a hypoxia- inducible promoter. In
addition, respiration of 10% O2 increased tumor hypoxia
in vivo and enhanced the antitumor effects. Taken
together, these results demonstrate that hypoxia- indu-
cible vectors may be useful for tumor-selective gene
therapy, although the problem of delivery of the vector
to the tumors, particularly to the hypoxic cells in the
tumors, is not addressed by these studies.
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Introduction
Hypoxia, a unique feature of human solid tumors, is
considered to be a major problem in cancer treatment [1] .
Clinical studies of patients with cervical, head, and neck
cancers, and soft tissue sarcomas treated with radiotherapy
or surgery have shown that local tumor control and overall
survival are significantly reduced in patients with hypoxic
tumors compared to those with better -oxygenated tumors
[2–6] . These results have been supported by the findings
that hypoxia in the tumor microenvironment can accelerate
malignant progression and metastasis [7] . Tumor hypoxia
has been proposed to stimulate angiogenesis and tumor
development through the induction of proangiogenic pro-
teins, such as vascular endothelial growth factor (VEGF). A
number of genes, including erythropoietin (Epo) and various
glycolytic enzymes, are also induced under hypoxic con-
ditions [8–10] . A hypoxia- responsive element (HRE) was
originally reported in the 30 flanking region of the human and
mouse Epo genes, and a hypoxia- inducible factor 1 (HIF-1)
activates transcription by binding to the Epo HRE [11,12] .
Similar HIF-1 binding sites have been found in regulatory
regionsofotherhypoxia- induciblegenes [13–15] .TheHIF-1
transcription factor is composed of an oxygen-sensitive
HIF-1 subunit and a constitutively expressed HIF-1
subunit. Recently, a murine hepatoma cell line lacking a
HIF-1 subunit showed decreased expression of hypoxia-
inducible genes in situ, reduced vascularity, and slower
growth as tumor xenografts [16] , suggesting that HIF-1–
mediated gene regulation is essential for angiogenesis and
tumor development in vivo. Such regulatory mechanisms for
hypoxia- responsive gene expression could provide a poten-
tial target for tumor-specific therapeutic approaches.
A number of fundamental problems must be overcome for
cancer gene therapy in vivo to be realized. One requirement
for tumor-specific gene therapy is to regulate expression of
the therapeutic gene at a specific site or in a particular cell
type in a tumor. Regulated gene expression can be achieved
through transcriptional targeting by the use of inducible
enhancer /promoter units. Several strategies for transcrip-
tional targeting have been proposed and used for gene
therapy, including a tyrosinase gene promoter for melano-
mas [17] , a prostate-specific antigen promoter for prostate
cancers [18] , and an  - fetoprotein promoter for hepatomas
[19] . We and others have proposed that hypoxia may
represent a means to target gene expression selectively to
tumors [1,20–22] . Solid tumors have abnormal vasculature
with sluggish, irregular blood flow, and the resulting hypoxia
provides a clear distinction between tumor and normal
tissues, except for certain pathological conditions. However,
to date, there have been no reports of successful in vivo
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implementation of gene therapy exploiting tumor hypoxia.
Possible reasons include inadequate specificity or potency of
the vectors expressing therapeutic genes. An earlier study of
Dachs et al. [21 ] , using mouse phosphoglycerate kinase-1,
thymidine kinase, and 9-27 promoters with HRE driving a
cytosine deaminase (CD) gene in stably transfected cells,
reported a 5.4- fold increase in sensitivity to 5- fluorocytosine
(5-FC) as judged by an IC50 assay after 16 hours of
hypoxia. Also, studies by Ruan et al. [23] , who transfected a
reporter plasmid with multiple copies of HRE into U-87 MG
and U-251 MG-NCI human brain tumor cells, showed that
increased expression levels of 4- to 12- fold could be
achieved, as well as increased apoptosis in hypoxia when
the hypoxia-activated promoter was used to drive the BAX
gene. We have previously shown that a vector with HRE
derived from the human VEGF gene exhibited a significant
increase in gene expression under hypoxia when transiently
transfected into human tumor cells [22] . In our recent study
to develop hypoxia- inducible vectors with higher levels of
gene expression [24] , we found that a construct composed
of 5HRE ligated to a human CMV minimal promoter (5HRE/
hCMVmp) increased gene expression over 500- fold in
response to hypoxia for 18 hours, reaching levels compara-
ble to that obtained by the CMV/IE promoter in transient
transfection assays. In addition, we also examined whether
the 30 UTR of the human VEGF gene would confer increased
posttranscriptional mRNA stability under hypoxic conditions.
However, despite increases in the hypoxic /aerobic ratio of
luciferase activity, gene expression with 30 UTR was lower
due to mRNA destabilization by AU-rich elements, so that
we found no benefit from the inclusion of the 30 UTR in our
vectors. Thus, a 5HRE/hCMVmp construct may be superior
in terms of robust hypoxia responsiveness and quantitative
production of a desired gene to obtain tumor-specific gene
expression through the exploitation of tumor hypoxia.
5-Aziridinyl 2,4-dinitrobenzamide (CB 1954) , originally
synthesized over 30 years ago, exhibits a dramatic and
highly specific antitumor activity against rat Walker 256
carcinoma cells [25] . This antitumor effect is due to efficient
drug activation by rat DT-diaphorase [26] . CB 1954 entered
into clinical trials in 1970s, but little antitumor activity was
observed as human DT-diaphorase is much less active in
reduction of CB 1954 than the rat enzyme. Recent studies
revealed that amino acid difference at residue 104 between
human and rat enzymes is responsible for the catalytic
differences to CB 1954 [27] . A nitroreductase (NTR) gene
isolated from Escherichia coli has been demonstrated to
activate the prodrug CB 1954 to its toxic form approximately
90- fold more rapidly than rat DT-diaphorase, suggesting the
possibility of using CB 1954 with NTR in antibody-directed
enzyme prodrug therapy (ADEPT) [28,29] . Also, several
authors have suggested using NTR with CB 1954 for gene-
directed enzyme prodrug therapy (GDEPT) [30–34] .
The purpose of this study is to show proof -of -principle
for performance of our hypoxia- inducible system with
plasmids expressing an E. coli NTR as a prodrug-
activating enzyme. We examined whether selective expres-
sion of this enzyme could be detected under hypoxic
conditions in stably transfected human tumor cells in vitro.
We also investigated the efficacy of the prodrug CB 1954
Figure 1. The luciferase reporter assay using stably transfected cells under
aerobic and hypoxic conditions. (A ) Schematic diagram of the luciferase
reporter plasmids with CMV / IE and 5HRE /hCMVmp expression units. (B )
Comparison of the luciferase activity under aerobic ( clear columns ) and
hypoxic (black columns ) conditions. Stably transfected clones with the
plasmids shown above were exposed to aerobic and hypoxic conditions
(0.02% O2 ) for 6 hours and assayed for luciferase activity. The luciferase
activities were normalized to that of a CMV / IE - luc clone under aerobic
conditions. The error bars show the standard deviations (SD) of four
independent samples. (C ) The time course of luciferase activity after
reoxygenation following hypoxic treatment of a 5HRE /hCMVmp - luc clone.
The cells were treated under hypoxic conditions for 24 hours and then
returned to aerobic conditions. The relative luciferase activity to its peak value
was shown. Bars, SD of four independent experiments.
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in inducible sensitization in response to hypoxia and tested
the antitumor effects of CB 1954 using tumor xenografts in
SCID mice in which we manipulated the level of O2
respired. Our results suggest that hypoxia- inducible
promoters with GDEPT may provide a means of selectively
producing cytotoxicity in solid tumors.
Materials and Methods
Culture and Hypoxic Treatment
HT1080 human fibrosarcoma cells were obtained from
the American Type Culture Collection (Rockville, MD) and
cultured in  -MEM with 10% FCS in a well -humidified
incubator with 5% CO2 at 378C. For transfection experi-
ments, 5105 exponentially growing cells were plated on the
culture dish overnight as described previously [22] . Hypoxic
conditions were achieved using prewarmed aluminum
hypoxic chambers [35] by evacuation and gassing with
95% N2/5% CO2, and then the tightly sealed chambers were
incubated at 378C. Some experiments were also performed
in an anaerobic tissue culture hood (Sheldon Corp.,
Cornelius, OR) . These two techniques produced similar
levels of hypoxia, and no difference was noted between
similar experiments performed using the two techniques.
Plasmid Construction and Transfection
The methods for construction of a 5HRE/hCMVmp as a
luciferase reporter vector were described previously [22] . In
this study, we replaced the luciferase gene with an E. coli
NTR gene as a prodrug-activating enzyme for CB 1954. The
NTR cDNA as a 651-bp fragment was obtained by polymer-
ase chain reaction (PCR) using Elongase enzyme mixture
(Gibco BRL, Gaithersburg, MD) with the following paired
primers: 50 -GAGACCATGGATATCATTTCTGTCGCCT-30
and 50 -AGAAGCGGCCGCCACTTCGGTTAAGGTGATGT-
TTTGCGG-30. The PCR conditions were 948C, 1 minute;
568C, 1 minute; 688C, 2 minutes for 35 cycles. The amplified
NTR gene fragment was digested and subcloned at NcoI–
NotI sites of pEF/myc/cyto vector ( Invitrogen, Carlsbad,
CA) to make a C-terminal fusion with a c-myc epitope and
checked by sequencing. To generate a hypoxia- inducible
expression vector for the NTR gene, the enhancer /promoter
sequence digested by KpnI and NcoI from a 5HRE/
hCMVmp vector was inserted into a pEF/myc/cyto vector
with NTR. Schematic diagrams of the plasmids are shown in
Figures 1A and 4A.
To obtain stable transfectants of the luciferase plasmid,
5 g of the plasmids was transfected into tumor cells with the
Superfect reagent (Qiagen, Valencia, CA) followed by
incubation for 3 hours. The culture dishes were washed
twice with PBS and fresh growth media added. At 48 hours
after transfection, the cells were trypsinized and plated for
clonal selection of stable transfectants in 400 g/ml G-418.
Several clones with good expression of the genes were
selected out of 48 individual clones in each group. Stable
transfectants of the CMV I/E-NTR and the 5HRE-NTR
plasmids were obtained in a similar manner.
To measure gene expression under hypoxic conditions,
stable transfectants were incubated for 6 to 18 hours under
aerobic or hypoxic conditions. After 2 hours of reoxygena-
Figure 2. Detection of E. coli NTR by immunofluorescence. Stable trans-
fectants of HT1080 cells were seeded on glass slides and were incubated
under aerobic or hypoxic conditions ( 0.02% O2 ) for 24 hours. The specimens
were treated with a 1:100 dilution of primary anti -myc antibody, followed by a
1:200 dilution of secondary antimouse IgG antibody conjugated with FITC as
described in Materials and Methods section. CMV / IE -NTR cells under
aerobic (A ) and hypoxic (B ) conditions. 5HRE /hCMVmp-NTR cells under
aerobic (C ) and hypoxic (D ) conditions.
Figure 3. Western blot analysis of NTR protein expression under aerobic and
hypoxic conditions. Protein lysates from wild - type HT1080, CMV/ IE -NTR,
and 5HRE /hCMVmp-NTR cells after treatment under aerobic or hypoxic
conditions (0.02% O2 ) for 6 to 18 hours were analyzed by SDS -PAGE and
immunoblotting with a monoclonal anti -myc antibody as described in
Materials and Methods section. A duplicate membrane was also treated for
an anti – - actin antibody as a loading control.
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tion, cell lysates were prepared with 400 l of passive lysis
buffer using a Dual Luciferase Assay kit (Promega Co.,
Madison, WI) and the luciferase activities were measured
with a luminometer, as described previously [22] .
In Vitro Assay for Antitumor Effects
The prodrug CB 1954, kindly provided by Dr. William R,
Wilson (University of Auckland School of Medicine, New
Zealand) , was dissolved in dimethylsulfoxide and stored
at 208C. Cells were seeded at 5103 cells /well in a 96-
well plate and incubated overnight. The growth media
were equilibrated under anaerobic conditions for at least
24 hours prior to use. The cells were treated under
hypoxic conditions for 24 hours with CB 1954, then
incubated for an additional 24 hours in air as increased
levels of hypoxia- induced expression persist after reox-
ygenation for 12 to 24 hours (Figure 1C ) . The cells were
washed in PBS, allowed to recover for 2 days, and
measured for growth inhibition effects by an MTS assay
using CellTiter96 AQ kit (Promega Co.) . The percent
control cell number was calculated as the absorbance
(proportional to cell numbers) of the treated cells divided
by that of the controls. The IC50 values were calculated as
the concentration that inhibits growth of tumor cells by
50% compared to untreated cells.
Detection of Hypoxia- Inducible NTR Gene Expression
Stable transfectants were seeded on Lab-Tek Chamber
Slides (Nalge Nunc International, Naperville, IL) . The cells
were treated under hypoxic conditions at 0.02% O2 or under
aerobic conditions for 24 hours, then fixed in 4% parafor-
maldehyde for 10 minutes, rinsed in PBS, and treated with
0.1% Triton X-100 for 5 minutes. After incubation with 1%
bovine serum albumin, the cells were treated with a 1:100
dilution of primary anti -myc antibody ( Invitrogen) for 1 hour,
followed by a 1:200 dilution of secondary antimouse IgG
antibody conjugated with fluorescein isothiocyanate (FITC;
Santa Cruz Biotechnology, Santa Cruz, CA). The specimens
were examined by a fluorescence microscope.
Western blots were also performed for quantitative
comparisons of protein levels. Wild- type HT1080 cells and
each transfected clone were plated on glass dishes, treated
under hypoxic or aerobic conditions for 6 to 18 hours, and
then were lysed in the sample buffer (4% SDS, 15%
sucrose, 100 mM Tris–HCl, and 5 mM EDTA) followed by
boiling for 5 minutes. Protein concentrations were measured
by Protein DC assay kit (Bio-Rad, Hercules, CA). Twenty-
five micrograms of total proteins was separated on a 10%
SDS-PAGE polyacrylamide gel, and transferred to nitro-
cellulose membrane (Schleicher&Schuell, Keene, NH).
Membranes were blocked by 5% nonfat dry milk in Tris -
buffered saline (TBS) for 30 minutes, incubated for 1 hour
with a 1:5000 dilution of anti -myc antibody for NTR-myc
fusion protein, washed in TBS three times for 5 minutes, and
then incubated with goat antimouse IgG conjugated with
alkaline phosphatase (Santa Cruz Biotecnology) . To con-
firm equal loading between samples, duplicate membranes
were examined with a control antibody for monoclonal anti–
 -actin (Sigma, St. Louis, MO) in parallel. Chemifluores-
cence signals on membranes were developed with ECF
Western blotting kit (Amersham, Arlington Heights, IL) and
scanned by Molecular Dynamics Storm System according
to the manufacturer’s instructions (Molecular Dynamics,
Sunnyvale, CA).
Figure 4. Sensitivity to CB 1954 of wild - type HT1080 cells and stable transfectants of NTR expression vectors. (A ) Schematic diagram of the plasmids with an E.
coli NTR gene combined with CMV / IE and 5HRE /hCMVmp expression units. (B ) Comparison of the sensitivity of wild - type HT1080 cells to CB 1954 under
aerobic (4 ) and hypoxic (~ ) conditions, of the CMV / IE -NTR clone under aerobic ( ) and hypoxic (o ) conditions. (C ) The sensitivity of the 5HRE /hCMVmp-
NTR clone to CB 1954 under aerobic (& ) and hypoxic (5 ) conditions. The error bars show SD of four to six independent experiments.
6
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Animal Studies
Human HT1080 cells and stably transfected clones were
injected intradermally in the midline of the back of SCID mice
and allowed to grow until the tumors reached a mean size of
100 mm3. Mice with a similar range of tumor sizes were
chosen and divided among different treatment groups, such
that the mean tumor sizes of four to six tumors per group
were similar. CB 1954 dissolved in 10% DMSO, 40%
polyethylene glycol 400, and 50% water at a concentration
of 5 mg/ml was injected intraperitoneally at the dose of
50 mg/kg body weight. For hypoxic treatment, mice were
placed in a plastic box and allowed to breathe 10% oxygen
for 4 hours and then normal air for 2 hours prior to drug
injections. Drug injections were performed twice, on day 0
(when the tumors were approximately 100 mm3) and 7 days
later. For the growth delay assay, the average tumor
volume was determined by measuring three orthogonal
diameters with calculation of the volume by the formula:
(d1d2d3) /6. The growth delay effect was determined as
the time required for the tumors to reach three times the
initial volume at day 0. The difference of the growth delay
effects between the control and each treatment group was
examined by Student’s t - test.
The oxygenation status of tumor xenografts was mea-
sured using a commercially available polarographic needle
electrode (pO2 histograph; Eppendorf, Hamburg, Germany)
using methods reported previously [36] . Briefly, tumor-
bearing mice were anesthesized by an intraperitoneal
injection of 0.5 mg/g pentobarbital (Abbott Laboratories,
North Chicago, IL) , placed in a specially designed jig to
reduce mobilization to a minimum, and the electrode was
inserted into the tumors followed by automatic measure-
ments moving through the tissue in steps of 0.2 mm. The
Mann-Whitney rank sum test was used to compare the
median pO2 values of tumors in air breathing with 10%
oxygen breathing animals as reported previously [36] .
Results
Hypoxia Responsiveness of a 5HRE/hCMVmp Construct in
Stable Transfectants
In our previous study, a 5HRE/hCMVmp construct
showed potent hypoxia- inducible gene expression using a
luciferase assay in transient transfected human tumor
cells [24] . To confirm the hypoxia responsiveness of this
construct in stably transfected cells, we generated a
luciferase reporter vector driven by a 5HRE/hCMVmp
expression unit along with a neomycin- resistant selectable
marker. After establishing stably transfected clones using
G418 selection, we assessed luciferase expression under
hypoxic conditions. Stable transfectants with a 5HRE/
hCMVmp- luc vector showed a 182- fold increase with a
6-hour hypoxic treatment, whereas a clone with CMV/IE-
luc vector showed no significant change in luciferase
activity following hypoxic exposure. The hypoxia/aerobic
ratio of luciferase activity was comparable to previously
published data using transient transfection. Importantly,
the luciferase activity of a 5HRE/hCMVmp- luc clone
under hypoxia reached levels similar to that of a CMV/
IE- luc clone (Figure 1B ) , indicating that our construct
could act as a strong enhancer /promoter in response to
hypoxia in these stable transfected clones, although the
expression levels might be affected by the sites of
integration.
We also examined the time course of luciferase activity
after reoxygenation following hypoxic exposure in a 5HRE/
hCMVmp- luc clone. Activities reached a maximum at the
end of the 24-hour period at approximately 280 times control
at 2 hours after reoxygenation, and then gradually decreased
over the next 24 hours (Figure 1C ) . As the half - life of
luciferase in the cells is about 3 hours [37] , the kinetics of
luciferase activity decay was more prolonged than expected.
A plausible explanation is that translation is still occurring
from mRNA induced under hypoxia, even after reoxygena-
tion inhibits HIF-1 activation.
Hypoxia- Induced Expression of the E. coli NTR gene
After establishing stably transfected clones with desired
plasmid constructs, we examined expression of the prodrug-
activating enzyme under hypoxic and aerobic conditions.
Each clone was seeded on a glass slide and was incubated
under hypoxic or aerobic conditions for 24 hours. Using an
anti -myc primary antibody and an FITC-conjugated anti-
mouse IgG secondary antibody, we assessed the protein
expression in the cells with fluorescent microscopy
(Figure 2 ) . For a CMV/IE-NTR clone, significant FITC
signal was detected under both hypoxic and aerobic
conditions. In contrast, with the 5HRE/hCMVmp-NTR
clone, only a background level was observed under aerobic
conditions, while a strong FITC signal occurred after a 24-
hour hypoxic treatment.
We quantitated NTR protein expression on aerobic and
hypoxic extracts of these clones by Western blots. As shown
in the Figure 3, NTR-myc tagged proteins have a molecular
mass of 26 kDa. In the left two lanes, the negative controls of
wild- type HT1080 cells showed only the  -actin bands. For
the CMV-NTR clone, NTR-myc bands were readily seen
under both aerobic and hypoxic conditions. In contrast, only
a trace amount of NTR protein was present under aerobic
conditions for 5HRE-NTR, whereas the expression levels
were markedly increased after 6- and 18-hour hypoxic
treatment in a time-dependent manner, demonstrating a
marked induction of NTR protein under hypoxic conditions in
the stably transfected cells with the 5HRE/hCMV-NTR
construct.
Hypoxia- Induced Sensitization to CB 1954
To examine whether the expression of E. coli NTR could
confer increased sensitivity of human tumor cells to CB 1954,
we assessed cytotoxicity /growth inhibition by a colorimetric
assay. The cells were treated with CB1954 under hypoxia for
24 hours and under aerobic conditions for an additional
24 hours, the prodrug was then removed, and growth
inhibition was measured after a further 2 days. For controls,
the cells were treated with drug for 48 hours under aerobic
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conditions. For positive controls, we chose a stable trans-
fectant with a CMV-NTR vector, which exhibited sensitivity
to CB 1954 with an IC50 value of around 10 to 20 M (Figure
4B ) . Under aerobic conditions, the 5HRE/hCMVmp-NTR
clone showed similar sensitivity to the wild- type HT1080
cells, indicating that this clone did not express sufficient
levels of NTR to affect prodrug activation. In contrast, the
IC50 value was reduced by 40- to 50- fold by the 24-hour
hypoxic treatment (Figure 4C ) . Thus, the hypoxia- inducible
sensitization of the transfectants in vitro correlated with their
increased NTR expression.
Tumor Xenografts in SCID Mice
To examine whether hypoxia- induced gene expression
could be activated in response to in vivo tumor hypoxia, we
transplanted wild- type and stably transfected clones of
HT1080 cells into SCID mice. We also treated tumor-
bearing mice by exposure to low oxygen to determine
whether increased tumor hypoxia in vivo increased anti-
tumor effect. The tumor take rates of each clone were
similar, and there were no significant differences in growth
rates between clones. For wild - type HT1080-derived
tumors, no growth delay was observed with two injections
Figure 5. Antitumor effects in xenografts in SCID mice determined by the
growth delay assay. Drug injections ( 50 mg /kg ) were performed twice, on
day 0 (when the tumors were approximately 100 mm3 ) and 7 days later. (A )
Tumors derived from wild - type HT1080 cells with no drug (& ) or CB 1954
(5 ) treatment. (B ) Tumors derived from the CMV / IE -NTR cells with no
drug (o ) or CB 1954 ( ) treatment. (C ) Tumors derived from the 5HRE /
hCMVmp -NTR cells with no drug (~ ) , CB 1954 (4 ) , or CB 1954 with
hypoxic breathing of 10% O2 for 4 hours prior to injection ( ) . The error bars
show SE of four to six tumors. The time to reach 3 treatment volume for the
tumors in the mice breathing 10% oxygen was significantly greater (P< .02 )
than those from controls.
 6
Figure 6. Tissue oxygen pressure measurements for transplanted tumors by
the Eppendorf microelectrode. Tumor - bearing SCID mice were anesthesized
and immobilized on a heating pad. Sequential measurements were done for
each tumor before (A ) and after (B ) 10% O2 breathing. The data are shown
as pooled histograms. The two groups were significantly different (P< .01 )
(Mann -Whitney rank sum test ) .
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of CB 1954 at 50 mg/kg. For CMV-NTR–derived tumors, a
substantial growth delay was evident with two injections of
CB 1954 when compared with the control (P=.032)
(Figure 5B ) . Tumors derived from 5HRE/hCMVmp-NTR
cells exhibited a small growth delay that did not quite reach
statistical significance (P=.052) at this drug dose. How-
ever, when the mice breathed 10% oxygen for 4 hours prior
to each of the two CB 1954 injections, there was a significant
tumor growth delay when compared with the control
(P=.018) , suggesting that hypoxic breathing enhanced
the expression of NTR gene in tumor tissues (Figure 5C ) .
To confirm the oxygenation status of HT1080 tumor
xenografts before and after 10% oxygen breathing, we
performed pO2 measurements using the Eppendorf elec-
trode. Tumors in anesthesized mice had a median pO2 of
7.1 mm Hg, with no significant differences between
different clones. During hypoxic breathing, tumors showed
a marked reduction of pO2 values with a median value of
1.0 mm Hg (Figure 6 ) . These changes of median pO2
values between air breathing and 10% oxygen breathing
animals were significant (P=.008) , as assessed by the
Mann-Whitney rank sum test.
Discussion
Hypoxia is a tumor-specific microenvironmental stress that
may provide an opportunity for tumor-specific therapy. In
recent reports, the average median pO2 for carcinomas of
the breast, prostate, head and neck, and cervix are in the
range of 10 to 15 mm Hg (1.3% to 2%), with most tumors
having areas with pO2 values <5 mm Hg [2–5,38,39] . In
contrast, normal tissues have a median pO2 of 40 to 60 mm
Hg with no values less than 10 mm Hg [36,38,40] . These
differences in oxygenation status provide the specificity for
hypoxia- responsive gene expression. In a study for HIF-1
DNA-binding activity in HeLa cells, a maximum response
was obtained at 0.5% oxygen with a half -maximum at about
1.5% oxygen (10 to 12 mm Hg) [41] . Our previous results
suggest that the 5HRE/hCMVmp construct gives maximum
gene expression in human tumor cells at an oxygen
concentration of 0.2% (1.5 mm Hg) and half -maximum
activity at 1% oxygen (5 to 7 mm Hg) [24] . Thus, the
activation of our hypoxia- inducible construct using the
human VEGF HRE is in the correct range for obtaining
selective gene expression in human tumors.
In the present studies, we used the E. coli NTR gene
driven by the hypoxia- inducible promoter with the drug
CB1954. This has been reported to be one of the most
promising enzyme/prodrug systems [34] . NTR efficiently
catalyses the reduction of CB 1954 to its 4-hydroxylamino
derivative in the presence of NADH or NADPH as a cofactor,
and is further converted by thioesters, such as acetyl co-
enzyme A, into a bifunctional alkylating agent [26] . In the
studies of ADEPT by Anlezark et al. [28 ] and Knox et al.
[29] , this activated species is reported to be some 104 times
more cytotoxic to V79 cells in vitro when the cells were
incubated with CB 1954 plus NTR in the presence of NADH.
In addition, the cytotoxicity of CB 1954 is not proliferation-
dependent, as it is for ganciclovir and 5- fluorouracil, and CB
1954 can kill noncycling cells by forming DNA crosslinks.
With regard to the bystander effect, studies have suggested
that a few percentages of activator cells produced a
substantial bystander cell killing effect using human tumor
cell lines in vitro [42 ] . To our knowledge, there have been no
data on bystander effect in in vivo tumor models with CB
1954.
The extent of antitumor effect in vivo depends on a variety
of factors, including the sensitivity of the target cells to
activated prodrug and the percentage of cells expressing the
enzyme. Stable transfectants expressing NTR by CMV or
hypoxia- inducible promoters in this study had an IC50 of 10
to 20 M with 48 hours of exposure and were 40- to 50- fold
more sensitive to CB 1954 than wild- type HT1080 cells.
However, these values are not as large as those reported in
other studies using similar treatment conditions. McNeish
et al. [33] reported that the IC50 of a transfected clone of a
human ovarian cancer line SKOV3 was 0.4 M compared to
an IC50 of 305 M for parental cells after a 72-hour
exposure. In a study by Friedlos et al. [42] , stable clones
of NTR expressing lines of WiDr, SKOV3, and V79 cells were
82- , 670- , and 2600- fold more sensitive than the parent
lines following a 96-hour exposure, respectively. Clearly,
considerable differences in sensitivity to the activated form of
CB 1954 are found among different cell lines. It has been
suggested that above a threshold level of enzyme activity in
stably transfected cells, the dose modification factor is not
simply related to levels of expression of NTR: where NTR is
in excess, the rate- limiting step may be the availability of
acetyl CoA required for the formation of the cytotoxic species
[42] . The availability of co- factors could also be the rate-
limiting step in this prodrug/enzyme system. To test another
prodrug-activating enzyme with CB 1954, we have also
established HT1080 clones transfected with mutated human
DT-diaphorase (Shibata et al., unpublished observations)
at amino acid residue 104, which has been shown to have
similar catalytic activity for CB 1954 to the rat enzyme [27] .
Interestingly, the IC50 for these clones was similar to that for
the stable clones in this study, suggesting that the HT1080
cell line may be intrinsically resistant to CB 1954.
Although breathing 10% oxygen greatly increased hypo-
xia of the transplanted tumors and augmented the antitumor
effect of CB 1954, this procedure can also affect the
oxygenation status of the normal tissue. Experimental data
obtained in our laboratory showed that breathing of 10%
oxygen resulted in a dramatic fall of a median pO2 to 15 mm
Hg in mouse subcutaneous tissue compared to a median in
air breathing of anesthesized mice of 40 mm Hg [36] .
However, because other tissues might have lower oxygen
levels caused by breathing 10% oxygen, it is unclear that this
strategy will increase the therapeutic ratio, and may not be a
realistic approach to cancer therapy. However, induction of
tumor hypoxia can be achieved by a variety of agents,
including flavone acetic acid [43] , tumor necrosis factor 
[44] , vinblastine, and combretastatins [45] .
Finally, HIF-1 expression has been reported to be
upregulated specifically during malignant progression of
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cancers. Previous studies demonstrated that loss of p53
function [46] , or activation of the Src and Ras oncogenes,
could increase HIF-1–mediated transcription by hypoxia
[47,48] . In addition, a recent analysis by immunohistochem-
istry has demonstrated that HIF-1 was overexpressed in a
number of specimens of primary cancers and metastasis
compared with the normal tissues, and that HIF-1
expression levels correlated with aberrant p53 accumulation,
bcl -2 expression, and Ki67 index [49] . These findings
indicate that HIF-1 expression may be a biomarker of
malignant progression and metastatic potential of human
cancers. Thus, HIF-1 dysregulation in human cancers, as
well as synergistic effects of abnormalities of tumor
suppressor genes and oncogenes on HIF-1–mediated
transcription, may enhance this approach for tumor-specific
gene therapy.
The present study suggests that hypoxia- inducible
vectors have the potential of providing selective expression
of therapeutic genes in the poorly oxygenated regions of
solid tumors. In vivo experiments using a variety of enzyme/
prodrug combinations and human tumor xenografts with
different hypoxic fractions are currently underway. However,
it has to be emphasized that the data we have reported are
from model studies and do not address the problem of
delivery of the hypoxia-activated promoters to the tumors.
Recent studies, however, with macrophages transduced
with a hypoxia- inducible promoter [50] clearly illustrate the
potential of hypoxia- targeted gene therapy, and the possi-
bility of combining it with a treatment such as radiotherapy,
which preferentially kills aerobic cells, is attractive.
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